Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 2
2005 1
2006 1
2007 2
2008 2
2009 2
2010 4
2011 4
2012 4
2013 4
2014 2
2015 4
2016 7
2017 6
2018 2
2019 7
2020 4
2021 9
2022 10
2023 8
2024 16
2025 11
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

105 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial.
Schuler M, Cuppens K, Plönes T, Wiesweg M, Du Pont B, Hegedus B, Köster J, Mairinger F, Darwiche K, Paschen A, Maes B, Vanbockrijck M, Lähnemann D, Zhao F, Hautzel H, Theegarten D, Hartemink K, Reis H, Baas P, Schramm A, Aigner C. Schuler M, et al. Among authors: hautzel h. Nat Med. 2024 Jun;30(6):1602-1611. doi: 10.1038/s41591-024-02965-0. Epub 2024 Apr 30. Nat Med. 2024. PMID: 38689060 Free PMC article. Clinical Trial.
SUVmax-Δ makes the difference.
Aigner C, Hautzel H, Ploenes T. Aigner C, et al. Among authors: hautzel h. Interact Cardiovasc Thorac Surg. 2022 Jul 9;35(2):ivac169. doi: 10.1093/icvts/ivac169. Interact Cardiovasc Thorac Surg. 2022. PMID: 35748731 Free PMC article. No abstract available.
Theranostics with somatostatin receptor antagonists in SCLC: Correlation of 68Ga-SSO120 PET with immunohistochemistry and survival.
Mavroeidi IA, Romanowicz A, Haake T, Wienker J, Metzenmacher M, Darwiche K, Oezkan F, Bölükbas S, Stuschke M, Umutlu L, Opitz M, Nader M, Hamacher R, Siveke J, Winantea J, Fendler WP, Wiesweg M, Eberhardt WEE, Herrmann K, Theegarten D, Schuler M, Hautzel H, Kersting D. Mavroeidi IA, et al. Among authors: hautzel h. Theranostics. 2024 Aug 26;14(14):5400-5412. doi: 10.7150/thno.98819. eCollection 2024. Theranostics. 2024. PMID: 39310095 Free PMC article.
FAPI PET in the Management of Lung Tumors.
Deleu AL, Shagera QA, Veldhuijzen van Zanten S, Flamen P, Gheysens O, Hautzel H. Deleu AL, et al. Among authors: hautzel h. Semin Nucl Med. 2025 Mar;55(2):202-211. doi: 10.1053/j.semnuclmed.2025.02.011. Epub 2025 Mar 3. Semin Nucl Med. 2025. PMID: 40037979 Review.
Diagnostic Accuracy of 68Ga-FAPI Versus 18F-FDG PET in Patients with Various Malignancies.
Hirmas N, Hamacher R, Sraieb M, Kessler L, Pabst KM, Barbato F, Lanzafame H, Kasper S, Nader M, Kesch C, von Tresckow B, Hautzel H, Aigner C, Glas M, Stuschke M, Kümmel S, Harter P, Lugnier C, Uhl W, Hadaschik B, Grünwald V, Siveke JT, Herrmann K, Fendler WP. Hirmas N, et al. Among authors: hautzel h. J Nucl Med. 2024 Mar 1;65(3):372-378. doi: 10.2967/jnumed.123.266652. Epub 2024 Feb 8. J Nucl Med. 2024. PMID: 38331453 Free article.
Fibroblast Activation Protein-Directed Imaging Outperforms 18F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial.
Kessler L, Schwaning F, Metzenmacher M, Pabst K, Siveke J, Trajkovic-Arsic M, Schaarschmidt B, Wiesweg M, Aigner C, Plönes T, Darwiche K, Bölükbas S, Stuschke M, Umutlu L, Nader M, Theegarten D, Hamacher R, Eberhardt WEE, Schuler M, Herrmann K, Fendler WP, Hautzel H. Kessler L, et al. Among authors: hautzel h. J Nucl Med. 2024 Aug 1;65(8):1188-1193. doi: 10.2967/jnumed.124.267473. J Nucl Med. 2024. PMID: 38960716 Free article.
Early years, advanced disease: The unmet need in young adults with non-small cell lung cancer.
Webendoerfer M, Wiesweg M, Winantea J, Keyl J, Hautzel H, Metzenmacher M, Theegarten D, Darwiche K, Bölükbas S, Doerr F, Graw A, Taube C, Stuschke M, Opitz M, Kalkavan H, Schuler M, Eberhardt WEE, Oezkan F. Webendoerfer M, et al. Among authors: hautzel h. Eur J Cancer. 2025 Nov 17;230:116011. doi: 10.1016/j.ejca.2025.116011. Epub 2025 Sep 24. Eur J Cancer. 2025. PMID: 41033152 Free article.
Prognostic Value of Fibroblast Activation Protein-Directed PET Imaging in Pleural Mesothelioma.
Kessler L, Schwaning F, Metzenmacher M, Pabst KM, Opitz M, Wiesweg M, Aigner C, Ploenes T, Bölükbas S, Doerr F, Stuschke M, Umutlu L, Nader M, Theegarten D, Eberhardt WE, Schuler M, Herrmann K, Fendler WP, Kersting D, Hautzel H. Kessler L, et al. Among authors: hautzel h. J Nucl Med. 2026 Mar 2;67(3):383-390. doi: 10.2967/jnumed.125.270906. J Nucl Med. 2026. PMID: 41506801
A Role for PET/CT in Response Assessment of Malignant Pleural Mesothelioma.
Sandach P, Seifert R, Fendler WP, Hautzel H, Herrmann K, Maier S, Plönes T, Metzenmacher M, Ferdinandus J. Sandach P, et al. Among authors: hautzel h. Semin Nucl Med. 2022 Nov;52(6):816-823. doi: 10.1053/j.semnuclmed.2022.04.008. Epub 2022 May 24. Semin Nucl Med. 2022. PMID: 35624033 Review.
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities.
Hirmas N, Hamacher R, Sraieb M, Ingenwerth M, Kessler L, Pabst KM, Barbato F, Lueckerath K, Kasper S, Nader M, Schildhaus HU, Kesch C, von Tresckow B, Hanoun C, Hautzel H, Aigner C, Glas M, Stuschke M, Kümmel S, Harter P, Lugnier C, Uhl W, Niedergethmann M, Hadaschik B, Grünwald V, Siveke JT, Herrmann K, Fendler WP. Hirmas N, et al. Among authors: hautzel h. J Nucl Med. 2023 May;64(5):711-716. doi: 10.2967/jnumed.122.264689. Epub 2022 Dec 29. J Nucl Med. 2023. PMID: 36581374 Free article. Review.
105 results